NOT-MH-21-105 - Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure
PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
PA-21-205 - Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
PAR-20-274 - New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional)
RFA-DA-22-040 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-22-040
PAR-20-221 - NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-20-221
PAR-20-224 - Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224
PAS-21-270 - AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
PAR-22-027 - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-22-027
National Institute on Drug Abuse (NIDA)
This Notice informs potential applicants of NIDA specific interest areas added to NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure".
The following sections of NOT-MH-21-105 have been modified to reflect participation and NIDA-Specific Interest Area language (changes shown in bold italics):
Issued by
National Institute on Drug Abuse (NIDA)
Purpose
The National Institute on Drug Abuse (NIDA) supports research that furthers our mission to advance science on HIV-related consequences of drug use and addiction, and to apply that knowledge to improve individual and public health.
Under this NOSI, NIDA is interested in research on effective health communication for improving HIV-related outcomes, particularly among people who use drugs (PWUD). Areas of particular interest are listed below, but are not limited to:
Developing, testing, and/or tailoring effective communication strategies, materials or campaigns to address topics related to HIV-related outcomes in PWUD such as:
HIV/drug use intervention and implementation strategies that incorporate testing hypotheses about how different communication approaches effect outcomes:
NIDA has particular interest in communication research that involves relevant audiences (e.g., providers, patients/clients, people who use drugs in the community) throughout the research process, and beyond formative research phases.
Applicants should review the NIDA AIDS Research Program regarding current priorities and current Funding Opportunity Announcements (available on NIDA'swebsite https://www.drugabuse.gov/about-nida/organization/offices/hiv-research-program-hrp), and consult with arelevant Program Officer before submitting an application.
Application and Submission Information
NIDA
This notice is effective immediately and includes receipt dates through May 8, 2024.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice. Applicable funding opportunity announcements include NIH parent announcements listed in NOT-MH-21-105 as well as NIDA specific announcements, including the following or any reissues of these announcements through the expiration date of this notice:
All other aspects of NOT-MH-21-105 remain unchanged.
Richard A. Jenkins, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: (301) 443-1923
Email: jenkinsri@nida.nih.gov